芦可替尼与真性红细胞增多症及骨髓纤维化患者非黑色素瘤皮肤癌风险的10年回顾性队列研究
该研究在斯坦福医学中心纳入564例真性红细胞增多症(PV)或骨髓纤维化(MF)患者,按年龄、性别、种族、Charlson合并症指数、诊断及随访时间匹配,其中188例暴露于芦可替尼至少4周。结果显示,芦可替尼暴露与NMSC风险升高相关(校正HR 2.69,95%CI 1.03-7.02),鳞状细胞癌(SCC)风险尤其升高(HR 3.24,95%CI 1.45-7.22),非JAK2突变者SCC风险更高(HR 7.40,95%CI 2.54-21.63)。
要点
- 芦可替尼暴露的PV或MF患者NMSC风险升高,校正HR为2.69。
- SCC风险升高更明显(HR 3.24),非JAK2突变者SCC风险达HR 7.40。
- 结果支持对服用芦可替尼的PV或MF患者考虑皮肤癌监测。
核心结论
- 真实世界数据显示,服用芦可替尼的PV或MF患者SCC风险升高,支持考虑皮肤癌监测。
研究设计与样本
- 斯坦福医学中心10年回顾性队列,共564例PV或MF患者,188例暴露于芦可替尼至少4周,376例未暴露。
- 按年龄、性别、种族、Charlson合并症指数、疾病诊断和随访时间进行匹配。
- 主要结局为芦可替尼暴露后NMSC(包括基底细胞癌和SCC)的风险比(HR),并校正协变量。
主要发现
- 芦可替尼暴露的PV或MF患者校正后NMSC的HR为2.69(95%CI 1.03-7.02)。
- 芦可替尼暴露与SCC相关,HR为3.24(95%CI 1.45-7.22)。
- 非JAK2突变患者SCC风险更高,HR为7.40(95%CI 2.54-21.63)。
临床怎么用
- 对PV或MF患者使用芦可替尼时应考虑皮肤癌监测,尤其关注SCC。
- 非JAK2突变患者SCC风险更高,可能需更密切关注。
局限性
- 回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials report occurrence of nonmelanoma skin cancers (NMSCs) with ruxolitinib in patients with polycythemia vera (PV) or myelofibrosis (MF); however, the level of risk and effect of covariates are not known in the real-world setting. OBJECTIVE: To systematically assess the risk of developing NMSC after ruxolitinib exposure in patients with PV or MF. METHODS: A 10-year retrospective cohort of patients with PV or MF at Stanford Medical Center was identified and matched according to age, gender, race, Charlson Comorbidity Index, disease diagnosis, and follow-up time. The main outcome measure was hazard ratio (HR) for NMSC (comprised of basal cell carcinoma and squamous cell carcinoma [SCC]) after ruxolitinib exposure, adjusted for covariates. RESULTS: The study cohort consisted of 564 patients (188 exposed to ruxolitinib for at least 4 weeks, 376 unexposed). Ruxolitinib-exposed patients with PV or MF had an adjusted NMSC HR of 2.69 (95% CI, 1.03-7.02). In particular, ruxolitinib exposure was associated with SCC (HR, 3.24; 95% CI, 1.45-7.22), with non-Janus kinase 2-mutated patients showing even higher SCC risk (HR, 7.40; 95% CI, 2.54-21.63). LIMITATIONS: Retrospective design. CONCLUSIONS: Our real-world results indicate that SCC risk is increased in patients with PV or MF taking ruxolitinib and support consideration of skin cancer monitoring.
引用
- Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2021. PMID: 34648874. doi:10.1016/j.jaad.2021.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。